Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide
Loredana Serpe, Margherita Gallicchio, Roberto Canaparo, Franco DosioDepartment of Drug Science and Technology, University of Turin, ItalyAbstract: Among the gynecological malignancies, ovarian cancer is the leading cause of mortality in developed countries. Treatment of ovarian cancer is based on...
Main Authors: | Serpe L, Gallicchio M, Canaparo R, Dosio F |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-01-01
|
Series: | Pharmacogenomics and Personalized Medicine |
Online Access: | http://www.dovepress.com/targeted-treatment-of-folate-receptor-positive-platinum-resistant-ovar-a15658 |
Similar Items
-
Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer
by: Luyckx M, et al.
Published: (2014-03-01) -
Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors
by: Ignace Vergote, et al.
Published: (2015-07-01) -
Recent Developments in Antibacterial Therapy: Focus on Stimuli-Responsive Drug-Delivery Systems and Therapeutic Nanoparticles
by: Roberto Canaparo, et al.
Published: (2019-05-01) -
Folate receptor: a potential target in ovarian cancer
by: Bartouskova Marie, et al.
Published: (2015-03-01) -
Folate-Receptor Positive Circulating Tumor Cell Is a Potential Diagnostic Marker of Prostate Cancer
by: Shenyi Lian, et al.
Published: (2021-10-01)